BE899790A - 3-(3-hydroxybutoxy)-1-butanol et sa preparation. - Google Patents

3-(3-hydroxybutoxy)-1-butanol et sa preparation.

Info

Publication number
BE899790A
BE899790A BE0/213036A BE213036A BE899790A BE 899790 A BE899790 A BE 899790A BE 0/213036 A BE0/213036 A BE 0/213036A BE 213036 A BE213036 A BE 213036A BE 899790 A BE899790 A BE 899790A
Authority
BE
Belgium
Prior art keywords
butanol
preparation
hydroxybutoxy
isomers
pure
Prior art date
Application number
BE0/213036A
Other languages
English (en)
French (fr)
Inventor
E Manghisi
A Salimbeni
Original Assignee
Luso Farmaco Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luso Farmaco Inst filed Critical Luso Farmaco Inst
Publication of BE899790A publication Critical patent/BE899790A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/03Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04Saturated ethers
    • C07C43/13Saturated ethers containing hydroxy or O-metal groups
    • C07C43/132Saturated ethers containing hydroxy or O-metal groups both carbon chains being substituted by hydroxy or O-metal groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/03Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14Unsaturated ethers
    • C07C43/164Unsaturated ethers containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/03Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14Unsaturated ethers
    • C07C43/178Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE0/213036A 1983-05-30 1984-05-30 3-(3-hydroxybutoxy)-1-butanol et sa preparation. BE899790A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT21352/83A IT1164254B (it) 1983-05-30 1983-05-30 3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione

Publications (1)

Publication Number Publication Date
BE899790A true BE899790A (fr) 1984-11-30

Family

ID=11180528

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/213036A BE899790A (fr) 1983-05-30 1984-05-30 3-(3-hydroxybutoxy)-1-butanol et sa preparation.

Country Status (8)

Country Link
US (1) US4584321A (cg-RX-API-DMAC7.html)
JP (1) JPS604146A (cg-RX-API-DMAC7.html)
BE (1) BE899790A (cg-RX-API-DMAC7.html)
DE (1) DE3419947A1 (cg-RX-API-DMAC7.html)
ES (1) ES8507449A1 (cg-RX-API-DMAC7.html)
FR (1) FR2547813B1 (cg-RX-API-DMAC7.html)
GB (1) GB2142623B (cg-RX-API-DMAC7.html)
IT (1) IT1164254B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6459003B1 (en) * 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
US6713507B2 (en) 2000-10-11 2004-03-30 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
BR0114619A (pt) 2000-10-11 2005-12-13 Esperion Therapeutics Inc Composto, composição farmacêutica, métodos para tratar ou prevenir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
BR0114623A (pt) 2000-10-11 2005-12-13 Esperion Therapeutics Inc Composto, composição farmacêutica, métodos para tratar ou prevenir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas
MXPA03003020A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de cetona y composiciones para el control del colesterol y usos relacionados.
US20050020694A1 (en) * 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20040192771A1 (en) * 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
JP2005522504A (ja) * 2002-04-10 2005-07-28 エスペリオン セラピューティクス,インコーポレイテッド パントラクトンおよびパントテン酸誘導体を含むアシル補酵素−aのミミック、その組成物、ならびにコレステロール管理の方法および関連の使用
HUE036646T2 (hu) 2003-01-23 2018-07-30 Esperion Therapeutics Inc Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra
WO2005068412A1 (en) 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CN103848726B (zh) * 2012-12-09 2017-09-05 河北凯盛医药科技有限公司 一种高纯度二羟二丁基醚及其制备方法
CN103304383B (zh) * 2013-06-18 2015-04-08 重庆医科大学 保胆健素的新合成方法
CN103319316B (zh) * 2013-06-24 2015-06-10 大连理工大学 一种二羟基二丁醚的绿色制备方法
CN103333057A (zh) * 2013-06-24 2013-10-02 大连理工大学 一种二羟基二丁醚的制备方法
CN104230674A (zh) * 2014-08-28 2014-12-24 成都邦泽生物医药科技有限公司 一种二羟基二丁醚的制备方法
WO2016149191A1 (en) 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
EP4438114A3 (en) 2019-06-21 2024-12-25 Esperion Therapeutics, Inc. Methods of making bempedoic acid and compositions of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT957008B (it) * 1967-11-09 1973-10-10 Luso Farmaco Inst Processo per la preparazione di eteri simmetrici di glicoli re canti ossidrili primari e secon dari
DE2218935C3 (de) * 1972-04-19 1980-01-31 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von wäßrigen Lösungen von N-Vinylpyrrolidonpolymerisaten

Also Published As

Publication number Publication date
DE3419947C2 (cg-RX-API-DMAC7.html) 1987-11-26
ES532802A0 (es) 1985-10-01
FR2547813B1 (fr) 1989-01-27
GB8411356D0 (en) 1984-06-06
GB2142623A (en) 1985-01-23
IT8321352A0 (it) 1983-05-30
ES8507449A1 (es) 1985-10-01
JPS604146A (ja) 1985-01-10
GB2142623B (en) 1987-04-15
IT8321352A1 (it) 1984-11-30
US4584321A (en) 1986-04-22
DE3419947A1 (de) 1984-12-06
FR2547813A1 (fr) 1984-12-28
JPS6241702B2 (cg-RX-API-DMAC7.html) 1987-09-04
IT1164254B (it) 1987-04-08

Similar Documents

Publication Publication Date Title
BE899790A (fr) 3-(3-hydroxybutoxy)-1-butanol et sa preparation.
FR2430410A1 (fr) Phenethanolamines et compositions pharmaceutiques en contenant
AU5432596A (en) Tricyclic compounds useful in the treatment of cell prolifer ative disorders
ES2117646T3 (es) Alteracion de la velocidad y el caracter del crecimiento del pelo.
NO900251L (no) Fremgangsmaate for behandling eller hindring av intrinsik aldret hud med retinoider.
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
BE900855A (fr) Compositions pour le traitement prophylactique de l'osteite et de l'osteomyelite.
JPS56166114A (en) Antiinflammatory medicinal composition
TNSN87012A1 (fr) Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques
FR2541115B1 (fr) Medicament renfermant un peptide en tant que principe actif pour le traitement des affections ulcereuses
DE69506686D1 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
BE901210A (fr) Nouveaux retinoides.
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
FR2455587A1 (fr) Derives de benzimidazole, leur preparation et utilisation dans le traitement des affections cardiovasculaires et compositions les contenant
YU46914B (sh) Metoksimetilna jedinjenja
FR2738150B1 (fr) Utilisation de la sulphasalazine et de ses metabolites pour la fabrication d'un medicament utile dans le traitement de l'insuffisance veineuse et des ulceres veineux
ES2002207A6 (es) Un metodo para producir derivados de glucosilmoranolina
FI870460A0 (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 5-substituerade oktahydroindolizinderivat och vid foerfarandet anvaendbara mellanprodukter.
BE1002121A4 (fr) Derives de la 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonine (ou -1,4-benzoxazonine), procede pour leur preparation et medicaments les contenant.
CA1267151C (en) SUBSTITUTED 7-THIABICYCLOHEPTANE ETHERS
FR2420595A1 (fr) Utilisation d'ethers tert-butyliques comme agents d'appretage de fibres
FR2358884A1 (fr) Compositions d'amino-alcools et leur procede de preparation et leur application notamment pour le traitement d'affections buccales
FR2698789B1 (fr) Utilisation de l'idazoxan et ses dérivés pour la préparation d'un médicament destiné au traitement de la maladie de Parkinson et de son évolution.
TNSN86165A1 (fr) Nouveaux ortho-anisamides, leur procede d'obtention et leurs applications therapeutiques
FR2355501A1 (fr) Nouvelles 2-(ethyl 2,2-disubstitue)-imidazolines, utiles notamment pour le traitement du diabete

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *ISTITUTO LUSO FARMACO D ITALIA S.P.A.

Effective date: 20040530